What's Happening?
Saluda Medical, a company specializing in medical devices for chronic neurological conditions, has received approval from the U.S. Food and Drug Administration (FDA) for its CAP24 paddle lead. This approval allows the company to market and sell the device in the U.S.,
targeting neurosurgeons and orthopedic surgeons who prefer paddle leads for spinal cord stimulation (SCS) procedures. The CAP24 paddle lead is designed to work with Saluda's Evoke System, which uses closed-loop neuromodulation technology to provide personalized therapy based on each patient's neural signals. The approval is expected to significantly expand Saluda's market reach, as paddle leads account for about 30% of all SCS implants in the U.S. Saluda plans a phased launch in the second half of 2026, with a broader rollout later in the year.
Why It's Important?
The FDA approval of the CAP24 paddle lead is a significant milestone for Saluda Medical, as it allows the company to expand its product offerings and reach a broader segment of the U.S. market. By targeting neurosurgeons and orthopedic surgeons, Saluda can increase its market share in the spinal cord stimulation sector, which is a growing field due to the rising prevalence of chronic pain conditions. The CAP24 paddle lead's unique design, which integrates with the Evoke System, offers a competitive advantage by providing more precise and effective pain management solutions. This development could lead to increased revenue for Saluda and enhance its position in the medical device industry.
What's Next?
Saluda Medical plans to initiate a phased U.S. launch of the CAP24 paddle lead in the latter half of 2026, with a full commercial rollout expected to follow. The company will focus on training surgeons and building field inventory to support the launch. As the surgical channel develops, Saluda anticipates a gradual increase in revenue from the new product. The company will likely continue to invest in research and development to further enhance its neuromodulation platform and expand its product portfolio.
